Augmentation of psychotherapy with d-cycloserine for anxiety disorders

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Ipser, Jonathan C ^a   Sander, Candice ^b   Seifan, Alon ^c   Stein, Dan J ^d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Die Wilgers ^*  (South Africa)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CYCLOSERINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; PSYCHOTHERAPY; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 70349161602     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007803     Document Type: Review

References (54)

1. American Psychiatric Association. Diagnostic and Statistical Man- ual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4thEdition. Washington, DC:American Psychiatric Association, 1994.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
4. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Psychopharmacol 2005;19(6):567-596
5. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive, Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002;3(4):171-199
6. Bandelow B, Ruther E. Treatment-resistant panic disorder. CNS Spectr 2004;9(10):725-739
7. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283(19):2529-2536
8. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory formeasuring depression. Archives of General Psychiatry 1961;4:561-571.
9. Black DW. Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders. CNS Spectr 2006;11(10 Suppl 12):29-33.
10. Blake DD, Weathers FW, Nagy LM, et al. A clinician rating scale for assessing current and lifetime PTSD: TheCAPS-1. BehaviorTherapy 1990;21:187-188
11. Boje KM, Wong G, Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 1993;603(2):207-214 (Pubitemid 23069216)
12. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: A review of meta-analyses. Clin Psychol Rev 2006;1:17-31.
13. Canadian PsychiatricAssociation. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51(8 Suppl 2): 9S-91S.
14. Deeks JJ, Altman DG, BradburnMJ. Statisticalmethods for examining heterogeneity and combining results fromseveral studies inmetaanalysis.. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2001.
15. Deeks JJ. Issues in the selection of a summary statistic for metaanalysis of clinical trials with binary outcomes. Statistics in medicine 2002;21(11):1575-1600
16. Deeks J, Higgins JPT, Altman D. editors. Analysing and presenting results. In: Higgins JPT, Green S editor(s). Cochrane Reviewers' Handbook 5.0.0 [updated February] Section 9;. Chichester, UK: John Wiley & Sons, Ltd., 2008.
17. Dickersin K, Min YI, Meinert CL. Factors influencing the publication of research results : follow-up of applications submitted to two substantial review boards. JAMA 1992;267(3):374-378
18. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry 2006;188:305-312.
19. Greenland S. Interpretation and choice of effectmeasures in epidemiologic analyses. Am J Epidemiol. 1987;125(5):761-768. (Pubitemid 17066475)
20. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.
21. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-55
22. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960;23:56-62.
23. Higgins JTP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(6):557-560
24. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Reviewers' Handbook 5.0.0 [updated February] Section 8;. Chichester, UK: John Wiley & Sons, Ltd., 2008.
25. Higgins JPT, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Reviewers' Handbook 5.0.0 [updated February] Section 16. Chichester, UK: John Wiley & Sons, Ltd, 2008.
26. Jones R, Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD003153; : CD003153]
27. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.. Archives of General Psychiatry 1994;51(1):8-19. (Pubitemid 24028993)
28. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. ArchGen Psychiatry 2005;62(6):593-602. (Pubitemid 40973434)
29. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 2003;117(2): 341-349 (Pubitemid 36384252)
30. Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry 2005;57(8):841-847 (Pubitemid 40488352)
31. Lee H, Kim JJ. Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats. J Neurosci 1998;18(20): 8444-8454 (Pubitemid 28465019)
32. Lee JL, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci 2006;26 (39):10051-10056 (Pubitemid 44477166)
33. Liebowitz MR. Social Phobia. Modern Problems in Pharmacopsychiatry 1987;22:141-173.
34. Marks IM, Swinson RP, Bas, og(lu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto.. Br J Psychiatry 1993;162:776-787
35. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000;157(5):669-682 (Pubitemid 30249642)
36. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005;88(1):27-45. (Pubitemid 41160411)
37. Moncrieff J, Churchill R, Drummond DC, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. International Journal of Methods in Psychiatric Research 2001;10(3):126-133 (Pubitemid 33014580)
38. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389. (Pubitemid 9136500)
39. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World health Organisation 1994;72:495-509.
40. Norberg MM, Krystal JH, Tolin DF. Ameta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008;63(12):1118-1126.
41. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J, International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological and operational definitions. International Journal of Neuropsychopharmacology 2002;5:181-191.
42. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004;61(7):714-719. (Pubitemid 38890806)
43. Popik, P, Wrobel, M, & Nowak, G. Chronic treatment with antidepressants affects glycine/NMDA receptor function: Behavioral evidence. Neuropharmacology 2000;39:2278-2287. (Pubitemid 30642770)
44. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994;257(1-2):7-12. (Pubitemid 24178543)
45. Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem 2004;11(5):510-516 (Pubitemid 39299697)
46. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using Pub Med. International Journal of Epidemiology 2002;31(1):150-153 (Pubitemid 34284917)
47. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. International Clinical Psychopharmacology 1996;11 Suppl 3: 89-95.
48. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4:1-115.
49. Spitzer R, Williams J, Gibbons M. Instructional manual for the struc- tured clinical interview for DSM-IV.. New York. NY: New York State Psychiatric Institute., 1996.
50. Szapiro G, Vianna MR, McGaugh JL, Medina JH, Izquierdo I. The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear. Hippocampus 2003;13(1):53-58 (Pubitemid 36305396)
51. Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003730. pub2.; : CD003730]
52. Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
53. Walker DL, Ressler KJ, Lu KT, DavisM. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-Cycloserine as assessed with fear-potentiated startle. J. Neurosci 2002;22:2343-2351
54. Yang YL, Lu KT. Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. Neuroscience 2005;134(1): 247-60.